Please Wait
Applying Filters...
menu
    • menu
    FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD

    Stock Recap
    #PipelineProspector

    Menu

    Dasatinib anhydrous

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 8,149Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/01/2025 Dr. Reddy\'s Laboratories
    India
    		 DR REDDYS LABORATORIES LTD 32400 DASATINIB (S)-PROPYLENE GLYCOL 2018-02-23 Active II Complete 2018-10-11 2018-08-31
    28/01/2025 Granules India Limited
    India
    		 GRANULES INDIA LTD 35270 DASATINIB 2020-11-23 Active II N/A